In PCa, TP53 mutations frequently coincide with TMPRSS2-ERG fusions, jointly accelerating malignancy through the activation of β-catenin-mediated pyrimidine biosynthesis 8. This evidence concerns the gene TP53 and posterior cortical atrophy.